Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously
doi: 10.1016/j.xcrm.2021.100263 74 VniantMMLuSCAtanganLKomorowskiRStanislausSChengYet al
Due to a short plasma half-life of native GLP-1, several synthesized GLP-1 receptor agonists (RAs) were developed for type 2 diabetes mellitus (DM) treatment
Track your progress systematically Weigh yourself weekly under consistent conditions (same time, same clothing, same scale)
doi: 10.3389/fendo.2025.1683419 Received 12 August 2025 Revised 04 December 2025 Accepted 30 December 2025 Published 23 January 2026 Volume 16 - 2025 Edited by Claudia Lagranha, Federal University of Pernambuco, Brazil Reviewed by Lei Zhao, China Medical University, China Michihiro Takahashi, Takahashi Psychiatric Clinic, Japan Sundararajan Mahalingam, University of Nebraska Omaha, United States Rodolfo Nunes, Federal University of Ceara, Brazil Updates Copyright 2026 Doval-Caballero, Ferreira-Hermosillo, Eugenio-Ponce, Garca-Senz, Ibarra-Salce, Tenorio-Rojo, Luna-Avila, Gete-Palacios, Prez-Hernndez, Rojas-Miln, Lpez-Cruz and Mndez-Hernndez
Retatrutides impact on weight loss, blood sugar control, and lipid profiles make it an effective tool in managing metabolic syndrome
